Corrected T1 (cT1) is the most appropriate diagnosis and monitoring tool for widespread adoption of resmetirom treatment in the United States
The use of cT1 to assign and monitor resmetirom treatment improves treatment allocation and reduces health system cost vs VCTE and liver biopsy.
Authors
- Mukesh G. Harisinghani (ORCID: https://orcid.org/0000-0003-0993-1947)
- Cayden Beyer
- Jose D. Vargas (ORCID: https://orcid.org/0000-0002-2005-567X)
- Niharika R. Samala (ORCID: https://orcid.org/0000-0002-1993-5223)
- Arjun Jayaswal (ORCID: https://orcid.org/0000-0002-3272-2695)
- Prasun K. Jalal (ORCID: https://orcid.org/0000-0001-5353-2324)
- Marika French (ORCID: https://orcid.org/0000-0002-9296-8320)
- Michael Fuchs (ORCID: https://orcid.org/0000-0002-8186-0779)
- Michael Ndaa
Institutions
- United States Department of Veterans Affairs (US)
- Baylor College of Medicine (US)
- Virginia Commonwealth University (US)
- Massachusetts General Hospital (US)
- VA Central California Health Care System (US)
- Center for Cancer Research (US)
- Department of Veterans Affairs (AU)
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
- Indiana University (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-08-27
- DOI
- https://doi.org/10.1080/13696998.2025.2550113
- Citations
- 2
- Primary Topic
- Complementary and Alternative Medicine Studies
- Type
- article
- Field-Weighted Citation Impact
- 4.76